RAP entered into the Sanofi discussions in good faith, and they are continuing and are positive and ongoing. Sanofi didn't choose to exercise their option recently. They are waiting for internal groups within their organisation. So game still on. FDA needs further information and RAP and Experian will be meeting soon. I don't know how long 'soon' means. Meanwhile RAP is continuing strong talks with telehealth providors in Europe. There will be a 'material' progress announcement shortly. I'm waiting
more later
RAP Price at posting:
9.3¢ Sentiment: Buy Disclosure: Held
